María Calasanz

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Physiology

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Agirre Xabier; Vilas-Zornoza Amaia; Jiménez-Velasco Antonio; Martin-Subero José Ignacio; Cordeu Lucia; Gárate Leire; San José-Eneriz Edurne; Abizanda Gloria; Rodríguez-Otero Paula; Fortes Puri; Rifón José; Bandrés Eva; Calasanz María José; Martín Vanesa; Heiniger Anabel; Torres Antonio; Siebert Reiner; Román-Gomez José; Prósper Felipe
Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.
Roman-Gomez Jose; Agirre Xabier; Jiménez-Velasco Antonio; Arqueros Victor; Vilas-Zornoza Amaia; Rodriguez-Otero Paula; Martin-Subero Iñaki; Garate Leire; Cordeu Lucia; San José-Eneriz Edurne; Martin Vanesa; Castillejo Juan Antonio; Bandrés Eva; Calasanz María José; Siebert Reiner; Heiniger Anabel; Torres Antonio; Prosper Felipe
Epigenetic regulation of microRNAs in acute lymphoblastic leukemia.
Sanz Miguel A; Montesinos Pau; Vellenga Edo; Rayón Consuelo; de la Serna Javier; Parody Ricardo; Bergua Juan M; León Angel; Negri Silvia; González Marcos; Rivas Concha; Esteve Jordi; Milone Gustavo; González José D; Amutio Elena; Brunet Salut; García-Laraña J; Colomer Dolors; Calasanz María J; Chillón Carmen; Barragán Eva; Bolufer Pascual; Lowenberg Bob
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of María Calasanz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Agirre Xabier; Vilas-Zornoza Amaia; Jiménez-Velasco Antonio; Martin-Subero José Ignacio; Cordeu Lucia; Gárate Leire; San José-Eneriz Edurne; Abizanda Gloria; Rodríguez-Otero Paula; Fortes Puri; Rifón José; Bandrés Eva; Calasanz María José; Martín Vanesa; Heiniger Anabel; Torres Antonio; Siebert Reiner; Román-Gomez José; Prósper Felipe
Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.
Cancer research 2009;69(10):4443-53.
2009: Roman-Gomez Jose; Agirre Xabier; Jiménez-Velasco Antonio; Arqueros Victor; Vilas-Zornoza Amaia; Rodriguez-Otero Paula; Martin-Subero Iñaki; Garate Leire; Cordeu Lucia; San José-Eneriz Edurne; Martin Vanesa; Castillejo Juan Antonio; Bandrés Eva; Calasanz María José; Siebert Reiner; Heiniger Anabel; Torres Antonio; Prosper Felipe
Epigenetic regulation of microRNAs in acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(8):1316-22.
2008: Sanz Miguel A; Montesinos Pau; Vellenga Edo; Rayón Consuelo; de la Serna Javier; Parody Ricardo; Bergua Juan M; León Angel; Negri Silvia; González Marcos; Rivas Concha; Esteve Jordi; Milone Gustavo; González José D; Amutio Elena; Brunet Salut; García-Laraña J; Colomer Dolors; Calasanz María J; Chillón Carmen; Barragán Eva; Bolufer Pascual; Lowenberg Bob
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
Blood 2008;112(8):3130-4.
2008: Fernández-Mercado Marta; Cebrián Virginia; Euba Begoña; García-Granero Marta; Calasanz María J; Novo Francisco J; Vizmanos José L; García-Delgado Marina
Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms.
Leukemia research 2008;32(10):1638-40.
2008: Ormazábal C; Hurtado C; Aranaz P; Erquiaga I; García-Delgado M; Calasanz M J; Novo F J; Vizmanos J L
Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs.
Leukemia research 2008;32(9):1485-7.
2008: José-Enériz Edurne San; Román-Gómez José; Cordeu Lucia; Ballestar Esteban; Gárate Leire; Andreu Enrique J; Isidro Isabel; Guruceaga Elizabeth; Jiménez-Velasco Antonio; Heiniger Anabel; Torres Antonio; Calasanz Maria José; Esteller Manel; Gutiérrez Norma C; Rubio Angel; Pérez-Roger Ignacio; Agirre Xabier; Prósper Felipe
BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia.
British journal of haematology 2008;142(4):571-82.
2008: Montiel-Duarte Cristina; Cordeu Lucia; Agirre Xabier; Román-Gómez José; Jiménez-Velasco Antonio; José-Eneriz Edurne San; Gárate Leire; Andreu Enrique J; Calasanz Maria José; Heiniger Anabel; Torres Antonio; Prósper Felipe
Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation.
Leukemia research 2008;32(5):709-16.
2007: Sáez Borja; Martín-Subero José I; Odero María D; Prosper Felipe; Cigudosa Juan C; Schoch Robert; Calasanz María J; Siebert Reiner
Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.
Oncology reports 2007;18(5):1099-106.
2007: Vicente C; Vázquez I; Marcotegui N; Conchillo A; Carranza C; Rivell G; Bandrés E; Cristobal I; Lahortiga I; Calasanz M J; Odero M D
JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(11):2386-90.
2007: Martín-Subero J I; Ibbotson R; Klapper W; Michaux L; Callet-Bauchu E; Berger F; Calasanz M J; De Wolf-Peeters C; Dyer M J; Felman P; Gardiner A; Gascoyne R D; Gesk S; Harder L; Horsman D E; Kneba M; Küppers R; Majid A; Parry-Jones N; Ritgen M; Salido M; Solé F; Thiel G; Wacker H-H; Oscier D; Wlodarska I; Siebert R
A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(7):1532-44.
2007: Guillem V M; Collado M; Terol M J; Calasanz M J; Esteve J; Gonzalez M; Sanzo C; Nomdedeu J; Bolufer P; Lluch A; Tormo M
Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(7):1413-22.
2007: Largo Cristina; Saéz Borja; Alvarez Sara; Suela Javier; Ferreira Bibiana; Blesa David; Prosper Felipe; Calasanz M Jose; Cigudosa Juan C
Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations.
Haematologica 2007;92(6):795-802.
2007: Suela J; Alvarez S; Cifuentes F; Largo C; Ferreira B I; Blesa D; Ardanaz M; García R; Marquez J A; Odero M D; Calasanz M J; Cigudosa J C
DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(6):1224-31.
2007: Sáez Borja; Martín-Subero José I; Lahortiga Idoya; Largo Cristina; Larrayoz María J; Odero María D; Prosper Felipe; Cigudosa Juan C; Siebert Reiner; Calasanz María J
Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
Cancer genetics and cytogenetics 2007;175(1):65-8.
2007: Román-Gómez José; Cordeu Lucia; Agirre Xabier; Jiménez-Velasco Antonio; San José-Eneriz Edurne; Garate Leire; Calasanz María José; Heiniger Anabel; Torres Antonio; Prosper Felipe
Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia.
Blood 2007;109(8):3462-9.
2007: Suela Javier; Largo Cristina; Ferreira Bibiana; Alvarez Sara; Robledo Mercedes; González-Neira Anna; Calasanz Maria José; Cigudosa Juan C
Neurofibromatosis 1, and Not TP53, seems to be the main target of chromosome 17 deletions in de novo acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(9):1151-2; author reply 1152-3.
2007: Bolufer Pascual; Collado Maria; Barragán Eva; Cervera José; Calasanz María-José; Colomer Dolors; Roman-Gómez José; Sanz Miguel A
The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia.
Haematologica 2007;92(3):308-14.
2007: Bolufer Pascual; Collado Maria; Barragan Eva; Calasanz María-José; Colomer Dolors; Tormo Mar; González Marcos; Brunet Salut; Batlle Montserrat; Cervera José; Sanz Miguel-Angel
Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia.
British journal of haematology 2007;136(4):590-6.
2006: Sáez Borja; Martín-Subero José I; Largo Cristina; Martín María C; Odero María D; Prosper Felipe; Siebert Reiner; Calasanz María J; Cigudosa Juan C
Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses.
Cancer genetics and cytogenetics 2006;169(2):143-9.
2006: Roman-Gomez Jose; Jimenez-Velasco Antonio; Agirre Xabier; Castillejo Juan A; Navarro German; Calasanz Maria J; Garate Leire; San Jose-Eneriz Edurne; Cordeu Lucia; Prosper Felipe; Heiniger Anabel; Torres Antonio
CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(16):4845-50.
2006: Sierra Magdalena; Alonso Alvaro; Odero M Dolores; Gonzalez M Belén; Lahortiga Idoia; Pérez José J; García Juan L; Gutiérrez Norma C; Calasanz María J; San Miguel Jesús F; Hernández Jesús M
Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain.
Leukemia research 2006;30(8):943-8.
2006: San José-Enériz Edurne; Agirre Xabier; Román-Gómez José; Cordeu Lucia; Garate Leire; Jiménez-Velasco Antonio; Vázquez Iria; Calasanz María José; Heiniger Anabel; Torres Antonio; Prósper Felipe
Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter.
British journal of haematology 2006;134(2):137-44.
2006: Sáez Borja; Martín-Subero José I; Odero María D; Prosper Felipe; Hernandez Roberto; Cigudosa Juan C; Siebert Reiner; Calasanz María J
Interphase FISH for the detection of breakpoints in IG loci and chromosomal changes with adverse prognostic impact in multiple myeloma with normal karyotypes.
Cancer genetics and cytogenetics 2006;167(2):183-5.
2006: Calasanz M J
[Cancer research new era]
Anales del sistema sanitario de Navarra 2006;29(2):173-6.
2006: Agirre Xabier; Román-Gómez José; Vázquez Iria; Jiménez-Velasco Antonio; Garate Leire; Montiel-Duarte Cristina; Artieda Paula; Cordeu Lucia; Lahortiga Idoya; Calasanz María José; Heiniger Anabel; Torres Antonio; Minna John D; Prósper Felipe
Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia.
International journal of cancer. Journal international du cancer 2006;118(8):1945-53.
2006: Vizmanos J L; Ormazábal C; Larráyoz M J; Cross N C P; Calasanz M J
JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(3):534-5.
2006: Agirre X; Román-Gómez J; Jiménez-Velasco A; Garate L; Montiel-Duarte C; Navarro G; Vázquez I; Zalacain M; Calasanz M J; Heiniger A; Torres A; Minna J D; Prósper F
ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.
Oncogene 2006;25(13):1862-70.
2006: Largo Cristina; Alvarez Sara; Saez Borja; Blesa David; Martin-Subero Jose I; González-García Ines; Brieva Jose A; Dopazo Joaquin; Siebert Reiner; Calasanz María J; Cigudosa Juan C
Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma.
Haematologica 2006;91(2):184-91.
2005: Solé Francesc; Luño Elisa; Sanzo Carmen; Espinet Blanca; Sanz Guillermo F; Cervera José; Calasanz María José; Cigudosa Juan Cruz; Millà Fuensanta; Ribera Josep Maria; Bureo Encarna; Marquez Maria Luisa; Arranz Eva; Florensa Lourdes
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Haematologica 2005;90(9):1168-78.
2005: Martín-Subero José Ignacio; Odero María Dolores; Hernandez Roberto; Cigudosa Juan Cruz; Agirre Xabier; Saez Borja; Sanz-García Eduardo; Ardanaz María T; Novo Francisco Javier; Gascoyne Randy D; Calasanz María José; Siebert Reiner
Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas.
Genes, chromosomes & cancer 2005;43(4):414-23.
2005: Agirre Xabier; Román-Gómez José; Vázquez Iria; Jiménez-Velasco Antonio; Larráyoz María J; Lahortiga Idoya; Andreu Enrique J; Márquez José; Beltrán de Heredia José M; Odero María D; Prósper Felipe; Calasanz María J
Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
Cancer genetics and cytogenetics 2005;160(1):22-6.
2005: de Mesa Reyes López; Sierrasesúmaga Luis; de Cerain Adela López; Calasanz María José; Patiño-García Ana
Pediatric meningosarcoma: clinical evolution and genetic instability.
Pediatric neurology 2005;32(5):352-4.
2005: Collado María; Barragan Eva; Bolufer Pascual; Calasanz María J; Larrayoz María J; Colomer Dolors; Munarriz Blanca; Verdeguer Amparo; Gutierrez Antonio; Batlle Montserrat; Sanz Miguel A
Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia.
Leukemia research 2005;29(5):595-7.
2005: Lahortiga Idoya; Vázquez Iria; Belloni Elena; Román José P; Gasparini Patrizia; Novo Francisco J; Zudaire Isabel; Pelicci Pier G; Hernández Jesús M; Calasanz María J; Odero María D
FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome.
Human genetics 2005;116(6):476-85.
2005: Valgañón Mikel; Giraldo Pilar; Agirre Xabier; Larráyoz María J; Rubio-Martinez Araceli; Rubio-Felix Daniel; Calasanz María J; Odero María D
p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
British journal of haematology 2005;129(1):53-9.
2005: Fraga Mario F; Ballestar Esteban; Villar-Garea Ana; Boix-Chornet Manuel; Espada Jesus; Schotta Gunnar; Bonaldi Tiziana; Haydon Claire; Ropero Santiago; Petrie Kevin; Iyer N Gopalakrishna; Pérez-Rosado Alberto; Calvo Enrique; Lopez Juan A; Cano Amparo; Calasanz Maria J; Colomer Dolors; Piris Miguel Angel; Ahn Natalie; Imhof Axel; Caldas Carlos; Jenuwein Thomas; Esteller Manel
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.
Nature genetics 2005;37(4):391-400.
2005: Lahortiga Idoya; Belloni Elena; Vázquez Iria; Agirre Xabier; Larrayoz María J; Vizmanos Jose L; Valgañón Mikel; Zudaire Isabel; Sáez Borja; Mateos María C; Di Fiore Pier Paolo; Calasanz María J; Odero María D
NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2.
Cancer genetics and cytogenetics 2005;157(2):151-6.
2005: Martínez-Ramírez Angel; Urioste Miguel; Melchor Lorenzo; Blesa David; Valle Laura; de Andrés Sara Alvarez; Kok Klaas; Calasanz Maria José; Cigudosa Juan Cruz; Benítez Javier
Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array.
Genes, chromosomes & cancer 2005;42(3):287-98.
2005: Odero M D; Grand F H; Iqbal S; Ross F; Roman J P; Vizmanos J L; Andrieux J; Laï J L; Calasanz M J; Cross N C P
Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(2):245-52.
2004: Vazquez I; Lahortiga I; Agirre X; Larrayoz M J; Vizmanos J L; Ardanaz M T; Zeleznik-Le N J; Calasanz M J; Odero M D
Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(12):2041-4.
2004: Sanz Cristina; Calasanz Maria J; Andreu Enrique; Richard Carlos; Prosper Felipe; Fernandez-Luna Jose L
NALP1 is a transcriptional target for cAMP-response-element-binding protein (CREB) in myeloid leukaemia cells.
The Biochemical journal 2004;384(Pt 2):281-6.
2004: Roman-Gomez Jose; Jimenez-Velasco Antonio; Castillejo Juan A; Agirre Xabier; Barrios Manuel; Navarro German; Molina Francisco J; Calasanz Maria J; Prosper Felipe; Heiniger Anabel; Torres Antonio
Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia.
Blood 2004;104(8):2492-8.
2004: Martínez-Ramírez Angel; Urioste Miguel; Alvarez Sara; Vizmanos José Luis; Calasanz Maria José; Cigudosa Juan Cruz; Benítez Javier
Cytogenetic profile of myelodysplastic syndromes with complex karyotypes: an analysis using spectral karyotyping.
Cancer genetics and cytogenetics 2004;153(1):39-47.
2004: Vizmanos José L; Larráyoz María J; Vázquez Iria; Odero María D; Hernández Roberto; Lahortiga Idoya; Novo Francisco J; Ardanaz María T; Calasanz María J
Remission of acute monocytic leukemia, secondary to treatment with epipodophyllotoxins, in a patient with t(8;16)(p11;p13) and MYST3-CREBBP fusion.
Cancer genetics and cytogenetics 2004;152(2):177-8.
2004: Lahortiga Idoya; Vázquez Iria; Agirre Xabier; Larrayoz María J; Vizmanos José L; Gozzetti Alessandro; Calasanz María J; Odero María D
Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.
Genes, chromosomes & cancer 2004;40(3):179-89.
2004: Pio Ruben; Zudaire Isabel; Pino Irene; Castaño Zafira; Zabalegui Natalia; Vicent Silvestre; Garcia-Amigot Fermin; Odero Maria D; Lozano Maria D; Garcia-Foncillas Jesus; Calasanz Maria J; Montuenga Luis M
Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.
Cancer research 2004;64(12):4171-9.
2004: Vizmanos José L; Novo Francisco J; Román José P; Baxter E Joanna; Lahortiga Idoya; Larráyoz María J; Odero María D; Giraldo Pilar; Calasanz María J; Cross Nicholas C P
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
Cancer research 2004;64(8):2673-6.
2004: González M Belén; Gutiérrez Norma C; García Juan L; Schoenmakers Eric F P M; Solé Francesc; Calasanz M José; San Miguel Jesús F; Hernández Jesús M
Heterogeneity of structural abnormalities in the 7q31.3 approximately q34 region in myeloid malignancies.
Cancer genetics and cytogenetics 2004;150(2):136-43.
2004: Sáez B; Martín-Subero J I; Guillén-Grima F; Odero M D; Prosper F; Cigudosa J C; Harder L; Calasanz M J; Siebert R
Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(3):654-7.
2004: Sanz Miguel A; Martín Guillermo; González Marcos; León Angel; Rayón Chelo; Rivas Concha; Colomer Dolors; Amutio Elena; Capote Francisco J; Milone Gustavo A; De La Serna Javier; Román José; Barragán Eva; Bergua Juan; Escoda Lourdes; Parody Ricardo; Negri Silvia; Calasanz María J; Bolufer Pascual;
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
Blood 2004;103(4):1237-43.
2004: Lahortiga Idoya; Agirre Xabier; Belloni Elena; Vázquez Iria; Larrayoz María J; Gasparini Patrizia; Lo Coco Francesco; Pelicci Pier Giuseppe; Calasanz María J; Odero María D
Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells.
Oncogene 2004;23(1):311-6.
2004: Vizmanos José L; Hernández Roberto; Vidal María J; Larráyoz María J; Odero María D; Marín Julián; Ardanaz María T; Calasanz María J; Cross Nicholas C P
Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(6):534-7.
2003: Agirre Xabier; Fontalba Ana; Andreu Enrique J; Odero Maria Dolores; Larráyoz María José; Montiel Cristina; Calasanz María José; Fernández-Luna José Luis; Prósper Felipe
Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response.
Haematologica 2003;88(12):1425-6.
2003: Agirre Xabier; Novo Francisco J; Calasanz María J; Larráyoz María J; Lahortiga Idoya; Valgañón Mikel; García-Delgado Marina; Vizmanos José L
TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia.
Molecular carcinogenesis 2003;38(4):201-8.
2003: García J L; Hernandez J M; Gutiérrez N C; Flores T; González D; Calasanz M J; Martínez-Climent J A; Piris M A; Lopéz-Capitán C; González M B; Odero M D; San Miguel J F
Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(10):2016-24.
2003: Steinemann Doris; Gesk Stefan; Zhang Yanming; Harder Lana; Pilarsky Christian; Hinzmann Bernd; Martin-Subero Jose Ignacio; Calasanz Maria Jose; Mungall Andrew; Rosenthal André; Siebert Reiner; Schlegelberger Brigitte
Identification of candidate tumor-suppressor genes in 6q27 by combined deletion mapping and electronic expression profiling in lymphoid neoplasms.
Genes, chromosomes & cancer 2003;37(4):421-6.
2003: Martínez-Ramírez A; Urioste M; Calasanz M J; Cigudosa J C; Benítez J
Array comparative genomic hybridization analysis of myelodysplastic syndromes with complex karyotypes. A technical evaluation.
Cancer genetics and cytogenetics 2003;144(1):87-9.
2003: Lahortiga Idoya; Vizmanos José L; Agirre Xabier; Vázquez Iria; Cigudosa Juan C; Larrayoz María J; Sala Francisco; Gorosquieta Ana; Perez-Equiza Katy; Calasanz María J; Odero María D
NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15).
Cancer research 2003;63(12):3079-83.
2003: Panizo Carlos; Patiño Ana; Lecumberri Ramón; Calasanz María José; Odero María Dolores; Bendandi Maurizio; Rocha Eduardo
Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases.
Cancer genetics and cytogenetics 2003;143(2):178-81.
2003: Odero María D; Carlson Katrin; Lahortiga Idoya; Calasanz María J; Rowley Janet D
Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations.
Cancer genetics and cytogenetics 2003;142(2):115-9.
2003: Gesk S; Martín-Subero J I; Harder L; Luhmann B; Schlegelberger B; Calasanz M J; Grote W; Siebert R
Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(4):738-45.
2003: Cigudosa Juan C; Odero Maria D; Calasanz M José; Solé Francesc; Salido Marta; Arranz Eva; Martínez-Ramirez Angel; Urioste Miguel; Alvarez Sara; Cervera Jose V; MacGrogan Donald; Sanz Miguel A; Nimer Stephen D; Benitez Javier
De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19.
Genes, chromosomes & cancer 2003;36(4):406-12.
2003: Vizmanos José L; Larráyoz María J; Lahortiga Idoya; Floristán Filomena; Alvarez Carmen; Odero María D; Novo Francisco J; Calasanz María J
t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia.
Genes, chromosomes & cancer 2003;36(4):402-5.
2003: Agirre Xabier; Vizmanos José Luis; Calasanz María J; García-Delgado Marina; Larráyoz María J; Novo Francisco J
Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients.
Oncogene 2003;22(7):1070-2.
2003: Baxter E Joanna; Kulkarni Shashikant; Vizmanos José-Luis; Jaju Rina; Martinelli Giovanni; Testoni Nicoletta; Hughes George; Salamanchuk Zoryana; Calasanz Maria José; Lahortiga Idoya; Pocock Christopher F; Dang Raymond; Fidler Carrie; Wainscoat James S; Boultwood Jacqueline; Cross Nicholas C P
Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
British journal of haematology 2003;120(2):251-6.
2002: Domingo-Domènech Eva; Boqué Concha; Aventin Ana; Calasanz Maria Jose; Valiente Alberto; Perez-Equiza Katy; Domingo-Clarós Alicia; Grañena Albert
Novel dic(16;18)(q11;p11) in two cases of Philadelphia chromosome positive acute B-cell lymphoblastic leukemia.
Cancer genetics and cytogenetics 2002;139(1):63-6.
2002: Esteller Manel; Fraga Mario F; Paz Maria F; Campo Elias; Colomer Dolors; Novo Francisco J; Calasanz Maria J; Galm Oliver; Guo Mingzhou; Benitez Javier; Herman James G
Cancer epigenetics and methylation.
Science (New York, N.Y.) 2002;297(5588):1807-8; discussion 1807-8.
2002: Odero María D; Vizmanos José L; Román José P; Lahortiga Idoya; Panizo Carlos; Calasanz María J; Zeleznik-Le Nancy J; Rowley Janet D; Novo Francisco J
A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome.
Genes, chromosomes & cancer 2002;35(1):11-9.
2002: Martín-Subero José Ignacio; Chudoba Ilse; Harder Lana; Gesk Stefan; Grote Werner; Novo Francisco Javier; Calasanz María José; Siebert Reiner
Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses.
The American journal of pathology 2002;161(2):413-20.
2002: Vizmanos José Luis; Larrráyoz María José; Odero María Dolores; Lasa Ramón; González Marcos; Novo Francisco Javier; Calasanz María José
Two new molecular PML-RARalpha variants: implications for the molecular diagnosis of APL.
Haematologica 2002;87(8):ELT37.
2002: Zudaire I; Odero M D; Caballero C; Valenti C; Martínez-Penuela J M; Isola J; Calasanz M J
Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas.
Histopathology 2002;40(6):547-55.
2002: Agirre X; García-Delgado M; Calasanz M J; Larráyoz M J; Novo F J; Vizmanos J L
Exon concatenation to increase the efficiency of mutation screening by DGGE.
BioTechniques 2002;32(5):1064-5, 1068-70.
2002: Martín-Subero José I; Harder Lana; Gesk Stefan; Schlegelberger Brigitte; Grote Werner; Martinez-Climent José A; Dyer Martin J S; Novo Francisco J; Calasanz María J; Siebert Reiner
Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci.
International journal of cancer. Journal international du cancer 2002;98(3):470-4.
2002: Martín-Subero José I; Gesk Stefan; Harder Lana; Sonoki Takashi; Tucker Philip W; Schlegelberger Brigitte; Grote Werner; Novo Francisco J; Calasanz María J; Hansmann Martin L; Dyer Martin J S; Siebert Reiner
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.
Blood 2002;99(4):1474-7.
2001: Martin-Subero J I; Siebert R; Harder L; Gesk S; Schwindt P; Bräuninger A; Willenbrock K; Steinemann D; Tiemann M; Calasanz M J; Grote W; Ludwig W D; Hansmann M L; Schlegelberger B
Cytogenetic and molecular characterization of a patient with simultaneous B-cell chronic lymphocytic leukemia and peripheral T-cell lymphoma.
American journal of hematology 2001;68(4):276-9.
2001: Marín C; Martínez-Delgado B; Meléndez B; Larrayoz M J; Martínez-Ramírez A; Robledo M; Cigudosa J C; Calasanz M J; Benítez J
Multiplex-polymerase chain reaction assay for the detection of prognostically significant translocations in acute lymphoblastic leukemia.
Haematologica 2001;86(12):1254-60.
2001: Alvarez S; MacGrogan D; Calasanz M J; Nimer S D; Jhanwar S C
Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization.
Genes, chromosomes & cancer 2001;32(3):285-93.
2001: Odero M D; Soto J L; Matutes E; Martin-Subero J I; Zudaire I; Rao P H; Cigudosa J C; Ardanaz M T; Chaganti R S; Perucho M; Calasanz M J
Comparative genomic hybridization and amplotyping by arbitrarily primed PCR in stage A B-CLL.
Cancer genetics and cytogenetics 2001;130(1):8-13.
2001: Hernández J M; Martín G; Gutiérrez N C; Cervera J; Ferro M T; Calasanz M J; Martínez-Climent J A; Luño E; Tormo M; Rayón C; Díaz-Mediavilla J; González M; González-San Miguel J D; Pérez-Equiza K; Rivas C; Esteve J; Alvarez M del C; Odriozola J; Ribera J M; Sanz M A;
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.
Haematologica 2001;86(8):807-13.
2001: González M; Barragán E; Bolufer P; Chillón C; Colomer D; Borstein R; Calasanz M J; Gómez-Casares M T; Villegas A; Marugán I; Román J; Martín G; Rayón C; Debén G; Tormo M; Díaz-Mediavilla J; Esteve J; González-San Miguel J; Rivas C; Pérez-Equiza K; García-Sanz R; Capote F J; Ribera J M; Arias J; León A; Sanz M A;
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.
British journal of haematology 2001;114(1):99-103.
2001: Martín-Subero J I; Harder L; Gesk S; Schoch R; Novo F J; Grote W; Calasanz M J; Schlegelberger B; Siebert R
Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia.
Cancer genetics and cytogenetics 2001;127(2):174-6.
2001: Odero M D; Carlson K; Calasanz M J; Lahortiga I; Chinwalla V; Rowley J D
Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping.
Genes, chromosomes & cancer 2001;31(2):134-42.
2001: Martín-Subero J I; Lahortiga I; Gómez E; Ferreira C; Larrayoz M J; Odero M D; García-Delgado M; Novo F J; Giraldo P; Calasanz M J
Insertion (22;9)(q11;q34q21) in a patient with chronic myeloid leukemia characterized by fluorescence in situ hybridization.
Cancer genetics and cytogenetics 2001;125(2):167-70.
2001: Odero M D; Matutes E; Valgañón M; Cigudosa J C; Bengoechea E; Calasanz M J
Complex karyotype in one patient with small cell variant of T-prolymphocytic leukemia. Analysis by G-banding and comparative genomic hybridization.
Haematologica 2001;86(3):324-5.
2001: Zudaire M I; Odero M D; Caballero M C; Valenti C; Martínez-Peñuela J M; Calasanz M J
[New cytogenetic prognostic markers in breast cancer]
Anales del sistema sanitario de Navarra 2001;24(1):25-37.
2000: Vizmanos J L; Agirre X; Calasanz M J; García M; Novo F J
[Genetic alterations in hematological neoplasias of lymphoid origin: implications for clinical practice]
Anales del sistema sanitario de Navarra 2000;23(3):451-65.
2000: López de Mesa R; Sierrasesúmaga L; Calasanz M J; López de Cerain A L; Patiño-García A
Nonclonal chromosomal aberrations induced by anti-tumoral regimens in childhood cancer: relationship with cancer-related genes and fragile sites.
Cancer genetics and cytogenetics 2000;121(1):78-85.
2000: Solé F; Espinet B; Sanz G F; Cervera J; Calasanz M J; Luño E; Prieto F; Granada I; Hernández J M; Cigudosa J C; Diez J L; Bureo E; Marqués M L; Arranz E; Ríos R; Martínez Climent J A; Vallespí T; Florensa L; Woessner S
Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica.
British journal of haematology 2000;108(2):346-56.
2000: López de Mesa R; Sierrasesúmaga L; Calasanz M J; López de Cerain A; Patiño A
[Characteristics and value of chromosome aberrations induced by antitumor treatments in pediatric patients with cancer]
Revista de medicina de la Universidad de Navarra 2000;44(1):15-24.
2000: Zhang Y; Matthiesen P; Harder S; Siebert R; Castoldi G; Calasanz M J; Wong K F; Rosenwald A; Ott G; Atkin N B; Schlegelberger B
A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization.
Genes, chromosomes & cancer 2000;27(1):52-8.
1999: Sanz M A; Martín G; Rayón C; Esteve J; González M; Díaz-Mediavilla J; Bolufer P; Barragán E; Terol M J; González J D; Colomer D; Chillón C; Rivas C; Gómez T; Ribera J M; Bornstein R; Román J; Calasanz M J; Arias J; Alvarez C; Ramos F; Debén G
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
Blood 1999;94(9):3015-21.
1998: Panizo C; Patiño A; Calasanz M J; Rifón J; Sierrasesumaga L; Rocha E
Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations.
Medical and pediatric oncology 1998;30(3):165-9.
1997: Calasanz M J; Cigudosa J C; Odero M D; García-Foncillas J; Marín J; Ardanaz M T; Rocha E; Gullón A
Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma.
British journal of haematology 1997;98(2):418-25.
1997: Calasanz M J; Cigudosa J C; Odero M D; Ferreira C; Ardanaz M T; Fraile A; Carrasco J L; Solé F; Cuesta B; Gullón A
Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations.
Genes, chromosomes & cancer 1997;18(2):84-93.
1995: Cigudosa J C; Calasanz M J; Odero M D; Marin J; Bengoechea E; Gullón A
A recurrent translocation, t(3;11)(q21;q13), found in two distinct cases of acute myeloid leukemia.
Cancer genetics and cytogenetics 1995;83(2):119-20.
1995: Cigudosa J C; Calasanz M J; Odero M D; Marín J; Bengoechea E; Gullón A
A variant t(14;17) in acute promyelocytic leukemia. Positive response to retinoic acid treatment.
Cancer genetics and cytogenetics 1995;80(2):160-1.
1994: Cigudosa J C; Calasanz M J; Odero M D; Prosper F; Etxaniz A; Marin J; Rifón J; Gullón A; Rocha E
Cytogenetic data in 41 patients with multiple myeloma. Karyotype and other clinical parameters.
Cancer genetics and cytogenetics 1994;78(2):210-3.
1994: Cigudosa J C; Calasanz M J; Pérez C; Rifón J; Cuesta B; Gullon A
Complex karyotype including 14q+ marker in a case of Waldenström's macroglobulinemia.
Cancer genetics and cytogenetics 1994;73(2):169-70.
1993: Cigudosa J C; Calasanz M J; García Delgado M; Gullón A
Cytogenetic patterns in 384 northern-Spanish patients with haematological disorders.
Hereditas 1993;118(1):79-85.
1992: Cigudosa J C; Calasanz M J; Gullón A; Prósper F; Cuesta B; Rifón J; Rocha E
A new case of acute lymphoblastic leukemia B-cell type with chromosomal rearrangements involving the T-cell receptor breakpoint at band 14q11.
American journal of hematology 1992;41(2):137-9.
1992: Cigudosa J C; Calasanz M J; Gullón A; Cuesta B; Rifón J; Rocha E
[Cytogenetic marker del(12p) in a case of acute myeloid leukemia M4 with eosinophilia and inv(16)]
Sangre 1992;37(2):125-7.
1990: Cigudosa J C; Calasanz M J; Gullon A; Ezpeleta I; Oyarzabal F J
Double minute chromosomes and monosomy 7 in a lymphatic blast crisis of chronic myeloid leukemia.
Cancer genetics and cytogenetics 1990;48(1):133-4.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

María Calasanz

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Physiology

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of María Calasanz (preview)

All Publications